Log in
NASDAQ:CDTX

Cidara Therapeutics Stock Forecast, Price & News

$2.30
-0.01 (-0.43 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.23
Now: $2.30
$2.36
50-Day Range
$1.99
MA: $2.70
$3.25
52-Week Range
$1.30
Now: $2.30
$4.45
Volume105,262 shs
Average Volume293,543 shs
Market Capitalization$101.06 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral Fc-conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and Coronavirus. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Read More
Cidara Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.76 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDTX
CUSIPN/A
Phone858-752-6170
Employees68

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.92 million
Book Value$0.67 per share

Profitability

Net Income$-41,090,000.00
Net Margins-662.48%

Miscellaneous

Market Cap$101.06 million
Next Earnings Date3/3/2021 (Estimated)
OptionableOptionable
$2.30
-0.01 (-0.43 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions

How has Cidara Therapeutics' stock been impacted by COVID-19?

Cidara Therapeutics' stock was trading at $2.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CDTX stock has decreased by 7.3% and is now trading at $2.30.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cidara Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cidara Therapeutics
.

What stocks does MarketBeat like better than Cidara Therapeutics?

Wall Street analysts have given Cidara Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cidara Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cidara Therapeutics' next earnings date?

Cidara Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for Cidara Therapeutics
.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) released its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.01. Cidara Therapeutics had a negative return on equity of 165.58% and a negative net margin of 662.48%.
View Cidara Therapeutics' earnings history
.

What price target have analysts set for CDTX?

5 Wall Street analysts have issued 1 year price objectives for Cidara Therapeutics' stock. Their forecasts range from $5.00 to $10.00. On average, they expect Cidara Therapeutics' stock price to reach $6.65 in the next year. This suggests a possible upside of 189.1% from the stock's current price.
View analysts' price targets for Cidara Therapeutics
.

Who are some of Cidara Therapeutics' key competitors?

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the following people:
  • Dr. Jeffrey L. Stein, Pres, CEO & Exec. Director (Age 65, Pay $797.1k)
  • Mr. Neil Abdollahian M.B.A., M.S., Chief Bus. Officer (Age 47, Pay $550.1k)
  • Dr. Taylor Sandison, Chief Medical Officer (Age 48, Pay $568.3k)
  • Dr. Kevin M. Forrest Ph.D., Founder and Chief Strategy Officer (Age 43)
  • Mr. James E. Levine, Chief Financial Officer (Age 49)
  • Mr. Paul Daruwala, COO & Chief Commercial Officer (Age 51)
  • Mr. Brady Johnson, Principal Accounting Officer, Controller & Director of Fin.
  • Ms. Jessica Oien J.D., Gen. Counsel & Sec. (Age 49)
  • Dr. Kenneth F. Bartizal Ph.D., Chief Devel. Officer (Age 69)
  • Mr. James M. Balkovec Ph.D., Sr. VP of Research

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

Who are Cidara Therapeutics' major shareholders?

Cidara Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.97%), Alethea Capital Management LLC (2.63%), State Street Corp (1.09%), Acadian Asset Management LLC (0.77%), Worth Venture Partners LLC (0.28%) and Wells Fargo & Company MN (0.22%). Company insiders that own Cidara Therapeutics stock include James E Levine, Jeffrey Stein, Jessica Oien, Neil Abdollahian and Paul Daruwala.
View institutional ownership trends for Cidara Therapeutics
.

Which major investors are selling Cidara Therapeutics stock?

CDTX stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Connor Clark & Lunn Investment Management Ltd., and Squarepoint Ops LLC. Company insiders that have sold Cidara Therapeutics company stock in the last year include Jessica Oien, and Neil Abdollahian.
View insider buying and selling activity for Cidara Therapeutics
.

Which major investors are buying Cidara Therapeutics stock?

CDTX stock was purchased by a variety of institutional investors in the last quarter, including Alethea Capital Management LLC, Worth Venture Partners LLC, BlackRock Inc., Acadian Asset Management LLC, State Street Corp, Wells Fargo & Company MN, Jeppson Wealth Management LLC, and GSA Capital Partners LLP. Company insiders that have bought Cidara Therapeutics stock in the last two years include James E Levine, and Jeffrey Stein.
View insider buying and selling activity for Cidara Therapeutics
.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cidara Therapeutics' stock price today?

One share of CDTX stock can currently be purchased for approximately $2.30.

How big of a company is Cidara Therapeutics?

Cidara Therapeutics has a market capitalization of $101.06 million and generates $20.92 million in revenue each year. The biotechnology company earns $-41,090,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Cidara Therapeutics employs 68 workers across the globe.

What is Cidara Therapeutics' official website?

The official website for Cidara Therapeutics is www.cidara.com.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.